All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 16 points (-0.1%) at 17,529 as of Tuesday, Aug. 18, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 984 issues advancing vs. 2,001 declining with 166 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the sector include Alexion Pharmaceuticals ( ALXN), down 1.2%, Biomarin Pharmaceutical ( BMRN), down 1.0%, Amgen ( AMGN), down 0.9%, Biogen ( BIIB), down 0.9% and Sanofi ( SNY), down 0.6%. Top gainers within the sector include Omeros ( OMER), up 72.2%, WellCare Health Plans ( WCG), up 5.6%, Express Scripts ( ESRX), up 1.6%, Cigna ( CI), up 1.5% and Grifols ( GRFS), up 1.5%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Becton Dickinson ( BDX) is one of the companies pushing the Health Care sector lower today. As of noon trading, Becton Dickinson is down $1.48 (-1.0%) to $147.12 on average volume. Thus far, 445,877 shares of Becton Dickinson exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $147.06-$148.47 after having opened the day at $148.02 as compared to the previous trading day's close of $148.60.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. Becton Dickinson has a market cap of $31.2 billion and is part of the health services industry. Shares are up 6.8% year-to-date as of the close of trading on Monday. Currently there are 9 analysts that rate Becton Dickinson a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Becton Dickinson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Becton Dickinson Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Perrigo ( PRGO) is down $1.25 (-0.6%) to $195.81 on light volume. Thus far, 373,962 shares of Perrigo exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $195.65-$198.42 after having opened the day at $196.47 as compared to the previous trading day's close of $197.06.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Perrigo Company plc, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Perrigo has a market cap of $28.7 billion and is part of the drugs industry. Shares are up 17.9% year-to-date as of the close of trading on Monday. Currently there are 5 analysts that rate Perrigo a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Perrigo as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Perrigo Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Medtronic ( MDT) is down $0.39 (-0.5%) to $78.35 on light volume. Thus far, 1.3 million shares of Medtronic exchanged hands as compared to its average daily volume of 5.1 million shares. The stock has ranged in price between $78.18-$78.72 after having opened the day at $78.37 as compared to the previous trading day's close of $78.74.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Medtronic plc manufactures and sells device-based medical therapies worldwide. Medtronic has a market cap of $109.7 billion and is part of the health services industry. Shares are up 9.1% year-to-date as of the close of trading on Monday. Currently there are 14 analysts that rate Medtronic a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Medtronic Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).